Clearance of apoptotic cells (efferocytosis) is a key modulator of the inflammatory response, and is dysregulated in several chronic inflammatory lung diseases, including chronic obstructive pulmonary disease and cystic fibrosis. Rho-GTPases are signaling molecules that differentially regulate efferocytosis: RhoA and its downstream effector Rho kinase inhibit efferocytosis, whereas Rac-1/Cdc42 stimulate it. Statins are 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors with broad antiinflammatory effects, largely based on their ability to block prenylation and membrane localization of RhoGTPases, including RhoA. Therefore, we hypothesized that statins would enhance efferocytosis by inhibiting RhoA. In vitro, lovastatin increased efferocytosis by both human and murine macrophages. The positive effect of lovastatin on efferocytosis was prevented by mevalonate, farnesylpyrophosphate, and geranylgeranylpyrophosphate, and was mimicked by specific inhibitors of farnesyltransferase and geranylgeranyltransferase. These results suggested that lovastatin acted by inhibiting HMG-CoA reductase and subsequent downstream prenylation events. In support of this notion, lovastatin decreased membrane localization of RhoA, but had no effect on expression of macrophage efferocytosis receptors. To determine whether lovastatin enhanced efferocytosis in vivo, mice were challenged intratracheally with apoptotic thymocytes, in the presence and absence of lovastatin or the Rho kinase inhibitor (Y-27632), and clearance of these apoptotic thymocytes was assessed. Both lovastatin and Y-27632 enhanced efferocytosis in vivo. These findings suggest that statins enhance efferocytosis in vitro and in vivo, and may ultimately play an important therapeutic role in diseases where efferocytosis isBackground: Prostacyclin is a major product of the cyclooxygenase (COX) pathway with both potent vasodilatory and antimitogenic properties. Previous studies have demonstrated an increase in cyclooxygenase 2 (COX-2), prostaglandin E 2 , cytosolic phosphoplipase A2 (cPLA 2 ), and vascular endothelial growth factor (VEGF), but decreased prostacyclin synthase (PGI 2 S) expression within lung tumors. Lung-specific overexpression of PGI 2 S has protective effects in both chemical-and tobacco smokeinduced murine models of lung tumorigenesis. Lastly, PGI 2 S expression within lung tumors may correlate with survival. Here, we hypothesize that an imbalance in COX-2, PGE 2 , and PGI 2 S may be important to the pathogenesis of other smoking-related lung diseases such as chronic obstructive pulmonary disease and that tobacco smoke may alter PGI 2 S expression. Design: We evaluated PGI 2 S expression in both normal and emphysematous human lung tissue samples by: (1 ) immunohistochemistry, (2 ) quantitative PCR, (3 ) Western analysis, and (4 ) both 6-keto PGF1␣ (the stable metabolite of prostacyclin) and PGE 2 levels by ELISA. In addition, we treated primary human pulmonary microvascular endothelial cells (HPMVEC) with varying concentrations of cigarette smoke extract (CSE). Treated cells were assessed for PGI 2 S, COX-2, VEGF, and cPLA 2 gene expression, and 6Keto-PGF1␣ and PGE 2 levels. Measurements and Results: In this study, we observed that human lung emphysema tissue exhibited lower PGI 2 S expression in the endothelium than normal lung tissue. Furthermore, in HPMVEC, CSE suppresses PGI 2 S gene expression while potently inducing COX-2, CPLA 2 , and VEGF expression. Pretreatment with potent antioxidants did not alter this imbalance with the exception of N-acetylcysteine (NAC), which reversed the induction of COX-2 by CSE. Conclusions: The main finding of this investigation is the demonstration of decreased PGI 2 S protein and mRNA in the lungs from patients with emphysema. CSE reduces the expression of the PGI 2 S gene and increases the expression of VEGF, COX-2, and cPLA 2 in HPMVEC. Decreased PGI 2 S expression is likely multifactorial, including oxidant stress, loss of alveolar capillary endothelial cells, nitric oxide-related suppression, and altered transcriptional control. In vitro work by our laboratory has demonstrated that PGI 2 S gene expression in lung carcinoma cell lines is partially controlled through methylation silencing. Our demonstration that PGI 2 S is diminished in both human emphysema tissue and in vitro by CSE, as well as similar observations in carcinomas of the lung, suggest that this imbalance may be an early tobacco smoke-induced event and relevant to the pathogenesis of both diseases.
